Table 3.

Overview of combined treatment and chemoprophylaxis

Screening outcome	Treatment offered	Rifamycin component
Leprosy	Leprosy MDT	Monthly rifampicin for 6–12 months
TB	TB treatment	Daily rifampicin for 6–12 months
RR-TB	DR-TB treatment+SDR	Single dose rifampicin
Eligible for TPT	3HP or 3RH	Weekly rifapentine or daily rifampicin for 3 months
Leprosy HHC	SDR-PEP	Rifampicin given at baseline and 1 year later
None of the above	SDR-MDA	Single dose of rifampicin

Screening outcomes are exhaustive but not mutually exclusive. The rifamycin component of each treatment strategy includes sufficient exposure to offer prevention for leprosy, in effect a MDA of leprosy chemoprophylaxis.

DR-TB, drug-resistant tuberculosis; HHC, household contact; 3HP, 3-months of weekly rifapentine and isoniazid; MDA, mass drug administration; MDT, multidrug treatment; NLP, national leprosy program; PCR, polymerase chain reaction; PEP, postexposure prophylaxis; 3RH, 3-months of daily rifampicin and isoniazid; RR-TB, rifampicin-resistant tuberculosis; SDR, single-dose rifampicin; TB, tuberculosis; TPT, tuberculosis preventive treatment.